Phase 2 N=30 CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas
Non-Hodgkin Lymphoma · Mycosis Fungoides
Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=66 Intraoperative Radiotherapy After Local Recurrence in Breast Cancer
Breast Carcinoma
Primary: The Tolerance of RIOP (Intra Operative Radiotherapy) in Patients With Delayed Local Recurrences, After a Second Conservative Treatment of Breast Cancer — 34; 19…
Phase 2 N=65 Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery
Breast Cancer
Primary: Number of Participants With Grade 3+ Treatment-related Skin, Fibrosis, and Breast Pain Adverse Events — 1 participants
N/A N=618 Retrospective Study on Referral Patterns for High Risk Patients Post Nephrectomy
Renal Cell Carcinoma
Primary: Follow-up Duration — 1.07 years
Phase 2 N=48 Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck
Recurrent Head and Neck Cancer · Carcinoma, Squamous Cell of Head and Neck
Primary: Progression Free Survival — 7.9 months
N/A N=278 Transoral Robotic Surgery for rECurrent Tumours of the Upper Aerodigestive Tract
Recurrent Head and Neck Cancer
Primary: Disease-free Survival at 2 Years — 111 Participants
Phase 3 N=162 Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer
Breast Cancer
Primary: Disease-free Survival — 57; 69 percentage of participants
Phase 1 N=17 Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy
Prostate Cancer · Prostatic Neoplasm
Primary: Maximum Tolerated Dose (MTD) — 40; 42.5 gray (Gy)
N/A N=7 Surgery With or Without Adjuvant Stereotactic Body Radiotherapy
Head and Neck Cancer
Primary: 1-year Local Control — NA; NA months
Phase 2 N=15 Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
Cancer of the Pharynx · Cancer of the Larynx · Cancer of the Neck
Primary: Toxicity — 0; 1; 2 participants
Phase 4 N=52 Retreatment of Recurrent Dupuytren's Contractures
Dupuytren's Disease
Primary: Clinical Success — 64.5; 45.0 percentage of particpants
N/A N=13 Radiation Therapy in Treating Patients With Recurrent Breast Cancer
Breast Cancer
Primary: Ipsilateral Breast Tumor Recurrence Rates — 0; 0 percentage of participants
N/A N=96 Different Patterns of Target Delineation in SBRT for Locally Advanced Pancreatic Cancer
Treatment
Primary: 1-year Progression Free Survival Rate — 9; 18 Participants
Phase 2 N=100 Ultrasound-Guided Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer Previously Treated With External-Beam Radiation Therapy
Prostate Cancer
Primary: Number of Patients With Late Treatment-related Gastrointestinal (GI) and Genitourinary (GU) Adverse Events (AE) — 12 Participants
Phase 3 N=2,108 Regional Anesthesia and Breast Cancer Recurrence
Breast Neoplasms
Primary: Number of Participants Who Had Breast Cancer Recurrence After Breast Cancer Surgery — 111; 102 participants — p=0.84
Phase 2 N=25 Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)
Non Small Cell Lung Cancer
Primary: Percentage of Participants With Progression Free Survival — 64 percentage of participants
N/A N=61 Sutent Rechallenge In mRCC Patients
Metastatic Renal Cell Carcinoma
Primary: Progression Free Survival With Sunitinib as First Line of Therapy — 18.4 months
Phase 2 N=121 Lerapolturev in Recurrent Malignant Glioma
Malignant Glioma
Primary: Number of Participants With Objective Radiographic Response — 5; 2 Participants
Phase 2 N=25 FACBC for Recurrent Prostate Cancer
Recurrent Prostate Cancer
Primary: The Presence of Cancer Tissue Inside of the Prostate Bed — 13; 8; 1; 0 Participants
Phase 2 N=42 Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
Lymphoma
Primary: Progression-free Survival — 18 participants
Phase 2 N=23 Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma
Melanoma
Primary: Ganglioside Expressed by Tumor Cells (GD2) — 3; 3; 3; 3 Participants
N/A N=12 Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer
Head and Neck Cancer
Primary: Duration of Local Control — 4.6 number of months to local failure
Phase 1 N=4 Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial
Histologically or Cytologically Confirmed Pancreatic Ca · Unresectable or Borderline Resectable Pancreatic Ca
Primary: Number of Participants With Dose Limiting Toxicity (DLT ) — 0; 1; 0; 0 Participants
Phase 2 N=22 Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma
Recurrent Glioma
Primary: Number of Participants With Adverse Events — 0; 1; 3; 3 Participants
N/A N=107 Recurrence Following Nonoperative Management of 1st Episode of Hinchey II Diverticulitis
Diverticulitis
Primary: Primary Study Endpoint — 26; 2 Participants
Phase 2 N=33 Radiotherapy for Solid Tumor Spine Metastases
Solid Tumor Spine Metastases
Primary: Number of Participants With Radiographic Recurrence at 12 Months — 3 Participants
Phase 2 N=25 Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence
Esophageal Squamous Cell Carcinoma
Primary: 1-year Relapse-free Survival Rate — 14.3 months
Phase 2 N=118 A Study LY2228820 for Recurrent Ovarian Cancer
Epithelial Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Phase 1b: Recommended Phase 2 Dose of LY2228820 in Combination With Gemcitabine and Carboplatin (Maximum Tolerated Dose [MTD]) — 200 milligrams (mg)
N/A N=90 Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Synchronous Metastasized Breast Cancer · Circulating Tumor Cells
Primary: Overall Survival (OS) — 34.6; 56.2 months — p=0.042
Phase 2 N=23 Autologous and Allogeneic Transplant for Relapsed Lymphoma
Non-Hodgkin's Lymphoma · Hodgkins Disease
Primary: Total Number of Subjects With a Complete Response (CR) Following Myeloablative Conditioning (MAC) and Autologous Stem Cell Transplantation (AutoSCT) — 4; 12 Participants